Can't find Agrylin? Learn about real alternatives like Hydroxyurea, Interferon, and Besremi that your doctor may consider for thrombocythemia.
If you're living with essential thrombocythemia or another myeloproliferative neoplasm and you can't find Agrylin (Anagrelide) at your pharmacy, you need options — and you need them fast. Going without a platelet-reducing medication isn't just uncomfortable; it can be medically dangerous.
In this article, we'll explain what Agrylin does, how it works, and walk you through the real alternatives your doctor may consider if you can't fill your prescription. This isn't about making a decision on your own — it's about knowing what to discuss with your hematologist so you can stay safe.
Agrylin is the brand name for Anagrelide, a platelet-reducing medication used to treat thrombocythemia secondary to myeloproliferative neoplasms. In simpler terms, it helps lower dangerously high platelet counts in people whose bone marrow makes too many platelets.
Conditions that may require Agrylin include:
Left untreated, high platelet counts increase the risk of blood clots, stroke, heart attack, and other serious thrombo-hemorrhagic events.
Agrylin belongs to a class of drugs called phosphodiesterase 3 (PDE3) inhibitors. It works by targeting megakaryocytes — the large bone marrow cells responsible for producing platelets. Anagrelide inhibits the maturation of these cells, which directly reduces platelet production.
This mechanism makes Agrylin unique among platelet-reducing agents. Unlike some alternatives that broadly suppress bone marrow activity, Agrylin is relatively selective for platelets, meaning it has less effect on red and white blood cell counts.
However, its PDE3 inhibitory activity can also affect the cardiovascular system, which is why patients taking Agrylin need regular heart monitoring including ECG checks.
Before switching to a different medication, make sure you've exhausted your options for finding Agrylin:
If you've done all of this and still can't get Agrylin, it's time to talk to your hematologist about alternatives.
Hydroxyurea is the most commonly prescribed first-line treatment for essential thrombocythemia and is often the medication patients tried before Agrylin.
Hydroxyurea inhibits DNA synthesis, which suppresses the growth of rapidly dividing cells in the bone marrow. This broadly reduces blood cell production, including platelets. Unlike Agrylin, it also affects white blood cell and red blood cell counts.
Pros: Well-studied with decades of safety data, inexpensive, widely available, effective at reducing both platelet and white blood cell counts.
Cons: Can cause suppression of other blood cell lines (anemia, low white blood cells), skin changes with long-term use, mouth sores, and theoretical concern about long-term leukemogenic risk (though this remains debated).
Pegylated Interferon Alfa-2a is increasingly used as a first- or second-line therapy for essential thrombocythemia, particularly in younger patients and those who want to avoid cytotoxic agents.
Interferons are naturally occurring proteins that modulate the immune system. In myeloproliferative neoplasms, pegylated interferon targets the abnormal stem cell clone directly, which can reduce not just platelet counts but also the underlying disease burden. Some patients achieve molecular responses, including reductions in the JAK2 mutation allele burden.
Pros: Can target the disease at the stem cell level, may achieve molecular remissions, preferred in younger patients, no leukemogenic risk.
Cons: Given by injection, can cause flu-like symptoms (especially early on), fatigue, mood changes, depression, autoimmune side effects, and liver function changes. Requires regular monitoring.
Ropeginterferon Alfa-2b, sold under the brand name Besremi, is a newer long-acting interferon that has generated significant excitement in the hematology world.
Like other interferons, Besremi modulates the immune system and targets the abnormal bone marrow clone. Its long-acting formulation allows for less frequent dosing — typically every two weeks — which improves convenience and tolerability compared to older interferons.
Pros: Less frequent dosing than older interferons, strong clinical trial results in ET, potential for disease modification, demonstrated superiority over Anagrelide in the SURPASS-ET trial.
Cons: Injection-based, can cause flu-like symptoms, expensive without insurance, may not be available at all pharmacies, off-label for ET until formal approval.
Busulfan is an older alkylating agent that is occasionally used in patients who cannot tolerate other treatments.
Busulfan works by damaging the DNA of rapidly dividing bone marrow cells, which reduces blood cell production including platelets.
Pros: Effective at reducing platelet counts, inexpensive, oral dosing.
Cons: Known leukemogenic potential (can increase risk of developing leukemia with long-term use), pulmonary toxicity, prolonged bone marrow suppression. Reserved for patients who have failed or cannot tolerate all other options.
If you need to switch from Agrylin to an alternative, here are some questions to bring to your hematologist:
Remember: never stop Agrylin abruptly. The medication carries a boxed warning about the risk of sudden platelet count spikes that can lead to stroke and other life-threatening events. Your doctor will plan any transition carefully.
Not being able to fill your Agrylin prescription is stressful, but you have real alternatives. Whether it's Hydroxyurea, Pegylated Interferon, Besremi, or in rare cases Busulfan, your hematologist can find a treatment that keeps your platelet counts in a safe range.
Start by trying to find Agrylin in stock near you. If that's not possible, have an honest conversation with your doctor about which alternative makes sense for your situation. And if cost is a factor, explore our guide on saving money on Agrylin and its alternatives.
Your health is too important to leave to chance. Stay proactive, stay informed, and work closely with your medical team.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
